Glenmede Trust CO Na Madrigal Pharmaceuticals, Inc. Transaction History

Glenmede Trust CO Na

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$120.4 - $237.13 $60,320 - $118,802	-501 Reduced 31.97%	1,066 $246,000
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $79,445 - $122,824	544 Added 53.18%	1,567 $228,000
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $236,374 - $314,142	1,023 New	1,023 $247,000
Q1 2019 May 14, 2019	SELL	$103.48 - $143.84 $7,036 - $9,781	-68 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $6,444 - $14,656	68 New	68 $7,000

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.94B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.